Atalanta Therapeutics

Stefan McDonough, Ph.D. presented mechanistic details on the antiseizure activity of Atalanta’s KCNT1-targeted di-siRNA ATL-201, results promising for treatment of a severe developmental epileptic encephalopathy and for the wider application of di-siRNA to disorders of the brain.?The CNS distribution and durability of di-siRNA were also featured in a panel discussion on the critical themes and emerging potential of oligonucleotide therapies. #AtalantaTX #RNALeaders

We glided across the ice for a great cause! Atalanta Therapeutics was proud to sponsor and participate in the Curling for Cure event at Broomstones Curling Club, supporting research for Huntington's Disease. We remain committed to advancing potential therapies for?Huntington's and other neurological disorders. A huge thank you to the Huntington's Disease Society of America (HDSA) for their incredible work! #AtalantaTX #HDSA

February 28th is Rare Disease Day, recognizing the millions of individuals around the world who are impacted by a rare disease.?Yesterday, we joined?the Rare Disease Day Walk in the Seaport with our biotech colleagues. It was inspiring to see everyone come together, donning their zebra stripes, to raise awareness and show support for those affected by rare diseases. The zebra stripes symbolize the uniqueness and rarity of these conditions. Together, we are committed to making significant strides in the ongoing fight against rare diseases, ensuring no one faces these challenges alone. #RareDiseaseDay #ShowYourStripes #TogetherWeCan

We are excited to share that our President and CEO, Alicia Secor, will be presenting at BioCapital Europe 2025 on February 6th at 12pm CET.?Join us to learn more about Atalanta Therapeutics innovative pipeline and our mission to pioneer new treatment options for CNS diseases with our di-siRNA platform. #BioCapital2025 #AtalantaTX

We are thrilled to announce the successful closing of our oversubscribed $97 million Series B financing. The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from RiverVest Venture Partners, Novartis Venture Fund, funds managed by abrdn, Pictet Group, Mirae Asset Financial Group, and GHR Foundation alongside existing investor F-Prime Capital.? ? We thank our investors, team, and community partners who are joining Atalanta Therapeutics’ mission to advance RNAi medicines for serious neurological diseases. https://bit.ly/40Q603V #EQTLifeScience #SanofiVentures #FPrime #abrdn #RiverVest #GHRFoundation #NovartisVentureFund #Pictet #MiraeAsset #SeriesBFinancing #AtalantaTX?

Bruno MDC Godinho delivered a presentation on the cutting-edge role of di-siRNAs in neurodegenerative disease at the 6th Annual CNS Drug Delivery Summit in Boston.?His talk offered a unique perspective on how RNA-based therapies can revolutionize the treatment landscape for neurodegenerative conditions and bring new hope for patients suffering from these debilitating diseases. #AtalantaTX

Benjamin Andreone, Ph.D. and Jennifer M. Lin, Ph.D. recently presented a poster at the American Epilepsy Society highlighting our latest data on our ATL-201 program for KCNT1-mediated epilepsy demonstrating that it effectively and durably suppresses or eliminates seizures in a mouse model of KCNT1-related epilepsy. A link to the poster can be found here: https://bit.ly/3ZWallL #AES #KCNT1 #AtalantaTX

Serena Hung, Atalanta’s Chief Medical Officer, recently provided an update on our progress with ATL-101 at the Innovation Forum at the Huntington Study Group (HSG) Meeting in Cincinnati, Ohio.??#AtalantaTX

Over 50 million people around the world are affected by epilepsy. At Atalanta, we celebrate the strength and resilience of those impacted by epilepsy and we are committed to advancing research that will lead to potential groundbreaking therapies. Share your purple power. ?#NEAM2024 #ShareYourPurplePower ?

Our Chief Scientific Officer, Aimee Jackson, PhD, represented Atalanta Therapeutics at the DIA/FDA Oligonucleotide-Based Therapeutics Conference in Washington, DC, last week, where she chaired a session on Translatability of CNS Safety and Pharmacology.?The conference brought together a group of industry researchers, academicians, and regulators to discuss the latest developments in the field of oligonucleotide-based therapeutics. #AtalantaTX